

Pacira BioSciences (PCRX)

\$52.72 (As of 07/29/20)

Price Target (6-12 Months): **\$62.00**

Long Term: 6-12 Months

Zacks Recommendation:

Outperform

(Since: 07/29/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5)

1-Strong Buy

Zacks Style Scores:

VGM:C

Value: D

Growth: B

Momentum: D

Summary

Pacira changed its name to Pacira BioSciences after acquiring MyoScience in 2019 following which, it added the latter's iovera system to its portfolio. Pacira's top line mainly comprises contribution from its marketed drug Exparel, which continues to maintain the momentum. The drug's label expansion to include administration via nerve block for prolonged regional analgesia is expected to further boost sales in the days ahead. Pacira's agreement with Nuance for the development and commercialization of Exparel in China is a tailwind. However, it remains heavily dependent on Exparel for growth. So, any regulatory setback for the drug will severely hurt the stock. Earnings estimates have moved north ahead of Q2 earnings. The company has a positive record of earnings surprises in the recent quarters.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$59.93 - \$27.46
20 Day Average Volume (sh)	741,252
Market Cap	\$2.2 B
YTD Price Change	16.4%
Beta	1.31
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Drugs
Zacks Industry Rank	Top 40% (102 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	65.6%
Last Sales Surprise	4.5%
EPS F1 Est- 4 week change	13.0%
Expected Report Date	08/13/2020
Earnings ESP	28.4%
P/E TTM	26.6
P/E F1	27.2
PEG F1	1.2
P/S TTM	5.1

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	120 E	127 E	133 E	143 E	541 E
2020	106 A	76 E	108 E	132 E	419 E
2019	91 A	103 A	105 A	122 A	421 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.60 E	\$0.74 E	\$0.78 E	\$0.91 E	\$3.48 E
2020	\$0.53 A	\$0.12 E	\$0.57 E	\$0.71 E	\$1.94 E
2019	\$0.22 A	\$0.41 A	\$0.48 A	\$0.56 A	\$1.67 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 07/29/2020. The reports text is as of 07/30/2020.


Overview

Parsippany, NJ-based Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019.

The company's flagship product, Exparel, was launched in 2012. Exparel is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. In 2012, the company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications. In 2017, Pacira signed an agreement with DePuy Synthes Sales Inc. (a subsidiary of J&J) to market and promote the use of Exparel for orthopedic procedures in the United States' market. The collaboration is expected to significantly expand use of Exparel across a broad range of surgical procedures. Exparel generated sales of \$407.9 million in 2019.

In June 2017, the company's board of directors approved a decision to discontinue all future production of DepoCyt(e) indicated for intrathecal treatment of lymphomatous meningitis. The company made the decision due to persistent technical issues specific to the DepoCyt(e) manufacturing process.

In 2019, Pacira generated total revenues of \$421 million, up 25% year over year.



Reasons To Buy:

▲ **Share Price Outperformance:** Shares of Pacira have outperformed the industry so far this year.

▲ **Exparel, the Growth Driver:** Demand for Exparel has been strong since its launch in April 2012, driven by growth within existing accounts along with increasing acceptance by major hospitals and orthopedic centers as it continues to be used in orthopedic procedures. Exparel revenues grew 23.2% year-over-year in 2019. Continued adoption of Exparel for transversus abdominis plane (TAP), infiltration procedures for abdominal and genitourinary surgeries should boost sales. In June 2019, the European Medicines Agency accepted the marketing authorization application for Exparel as a medicine to treat postsurgical analgesia. Further, an opinion from the Committee for Medicinal Products for Human Use is expected in the second half of 2020.

Exparel has been performing well since its launch in April 2012. Pacira is looking to expand Exparel's label in the animal health market as well.

▲ **Label Expansion of Exparel:** The company is working to expand Exparel's label, which should boost demand. In September 2019, Pacira completed enrollment in the phase III study on Exparel for treating pediatric patients aged from six to less than 17 years. In December 2019, Pacira announced positive results from the study. The subjects are undergoing spinal or cardiac surgeries. Results from this study will support a supplemental new drug application for Exparel in the United States regarding its label expansion to include children aged six years and above. There are currently no approved alternatives to opioids for managing severe postsurgical pain in pediatric patients.

Notably, Pacira is advancing Exparel in phase IV studies to expand its utilization in areas like cesarean section, spine and hip fracture.

In January 2020, Pacira announced that its phase IV study on Exparel, which evaluated patients undergoing Cesarean section (C-section), met the primary endpoint with a statistically significant decrease in total postsurgical opioid consumption all through 72 hours. Patient recruitment is also underway in a second C-section study (known as CHOICE). The study is designed to evaluate a completely opioid-free arm with Exparel including opioid-free spinal anesthesia. Moreover, the company is enrolling patients in another phase IV FUSION study for spine surgeries.

▲ **Strategic Collaborations and Educational initiatives:** The company's partnership with Johnson & Johnson (J&J) is a positive as J&J regularly opens doors for to new hospital systems for Pacira where the latter previously did not have any access. The company is collaborating closely with J&J on its overall strategy for Exparel. Its collaboration with the Cancer Treatment Centers of America, the Illinois Surgical Quality Improvement Collaborative, WellStar Health Systems and the University of Tennessee Medical Center are raising awareness around opioid alternatives and minimizing opioid use through a variety of joint initiatives.

In 2018, Pacira inked a deal with China-based Nuance for the development and commercialization of Exparel in China.

In April 2019, Pacira acquired the privately held MyoScience, Inc. following which, it added the latter's iovera system to its portfolio, which is highly complementary to Exparel as a non-opioid therapy.

▲ **Expansion Into Animal Health Market:** Pacira is looking to expand Exparel's label in the animal health market as well. In 2012, the company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications. Expansion into the animal health market will diversify Exparel's franchise and boost its commercial potential. There has been a steady rise in sales year over year from the bupivacaine liposome injectable suspension to Aratana for use in animals.

▲ **DepoFoam Platform for New Clinical Candidates:** DepoFoam drug delivery technology consists of microscopic spherical particles composed of numerous internal aqueous chambers containing an active drug ingredient. With the safety profile of DepoFoam platform, Pacira is advancing a development plan for intrathecal or subarachnoid delivery of a non-opioid analgesic for acute, sub-acute and chronic pain. The company also has several DepoFoam-based products in clinical development.

Risks

- **Heavily Dependent on Exparel:** Pacira's top line mainly comprises contribution from its marketed product. The company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. Exparel contributed 96.8% to total revenues in 2019. Hence, a decline in Exparel sales will adversely impact the company's top line.
 - **Pipeline Setbacks:** Pacira is not new to pipeline setbacks. The company suffered a major blow in March 2015 when it received a Complete Response Letter (CRL) from the FDA for its supplemental New Drug Application (sNDA) for Exparel. Pacira was seeking to expand the use of Exparel in nerve block to provide postsurgical analgesia. However, following a meeting with the FDA, the company initiated additional phase III studies and resubmitted a sNDA in October 2017. In February 2018, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee's (AADPAC) reviewed the company's sNDA, and voted six to four against approval of the expanded indication. Any similar setbacks will adversely impact the company's shares. We are also concerned about the lack of other candidates in the company's pipeline.
 - **Unfavorable Debt Profile:** Pacira has an unfavorable debt profile. As of Mar 31, 2020, the company's total debt (current and long-term debt) was approximately \$354 million. The company's cash, cash equivalents and marketable securities were nearly \$318 million as of the end of March 2020. Although the company has enough resources to pay off its short-term debt (\$4 million), its total debt exceeds its total assets, which may cause bankruptcy. However, the company's total debt to total capital of 48.6% as of March end demonstrates a decline from 49.8% at December end.
-

Last Earnings Report

Pacira's Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira reported first-quarter 2020 earnings of 53 cents per share, surpassing the Zacks Consensus Estimate of 32 cents and also increasing from the year-ago figure of 22 cents.

Total revenues too improved 16% from the year-earlier figure of \$91.3 million to \$105.7 million. Further, the top line beat the Zacks Consensus Estimate of \$101 million.

Quarter in Detail

Pacira's top line mainly comprises product revenues, other product sales and royalty revenues.

Exparel net product sales were \$101.3 million, up 12% from \$90.6 million in the year-ago quarter.

Exparel/bupivacaine liposome injectable suspension sales came in at \$1.2 million compared with \$0.3 million in the year-ago quarter.

Though the newly-added product iovera system generated sales worth \$2.3 million in the first quarter, the figure reflects a sequential decline of 28.1%.

Meanwhile, royalty revenues of \$0.9 million in the reported quarter were up 125% year over year.

Research and development (R&D) expenses (excluding stock-based compensation) rose 10.6% to \$14.6 million.

Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) decreased 9.2% year over year to \$38.3 million in the reported quarter.

2020 Outlook

Due to the COVID-19 pandemic situation, Pacira does not have enough visibility to forecast its adverse impact. As a result, the company is temporarily withdrawing its full-year financial guidance.

Recent Developments

In January 2020, Pacira announced that its phase IV study of Exparel in patients undergoing cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours.

In December 2019, Pacira announced positive results from its phase III PLAY study of Exparel, administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries.

Quarter Ending **03/2020**

Report Date	May 07, 2020
Sales Surprise	4.52%
EPS Surprise	65.62%
Quarterly EPS	0.53
Annual EPS (TTM)	1.98

Recent News

Provides Preliminary Results for Second Quarter – Jul 6

Pacira reported preliminary net sales of \$75.5 million for the quarter, ahead of the Zacks Consensus Estimate of \$54.1 million. However, revenues were down 26.4% year over year as the company's product sales were negatively impacted by the COVID-19 pandemic.

Preliminary net product sales of Exparel were \$73.8 million, down 26% from \$99.8 million in the year-ago quarter.

Exparel/bupivacaine liposome injectable suspension was \$0.8 million compared with \$0.9 million reported in the year-ago quarter.

Newly-added product iovera system generated sales worth \$1.4 million in the quarter compared with \$2 million a year ago.

Preliminary royalty revenues came in at \$0.3 million in the reported quarter compared with \$0.8 million a year earlier.

To Close Exparel Agreement with Depuy Synthes – Jul 2

Pacira announced that its agreement with DePuy Synthes Sales Inc. for jointly marketing and promoting the use of Exparel (bupivacaine injectable suspension) for orthopedic procedures in the United States will terminate on Jan 2, 2021.

Appoints Chief Medical Officer – May 4

Pacira announced that it has appointed Dr. Donald C. Manning as the chief medical officer, effective immediately.

Exparel Meets Key Goals in C-Section Study – Jan 7

Pacira announced that the phase IV CHOICE study on Exparel in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P<0.001).

The study also achieved the key secondary endpoint with Exparel demonstrating statistical significance for reduction in the incidence and severity of itching through 72 hours following surgery.

Valuation

Pacira's shares are up 18% in the year-to-date period and 21.8% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Medical sector are down 6.5% and up 1.4% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is down 3% while the sector is up 8.3%.

The S&P 500 index is up 1.3% in the year-to-date period and up 9.8% in the past year.

The stock is currently trading at 4.55X trailing 12-month sales per share, which compares to 2.94X for the Zacks sub-industry, 2.84X for the Zacks sector and 3.59X for the S&P 500 index.

Over the past five years, the stock has traded as high as 9.49X and as low as 2.35X, with a 5-year median of 4.39X. Our Outperform recommendation indicates that the stock will perform better than the market. Our \$62.00 price target reflects 5.27X trailing 12-month sales per share.

The table below shows summary valuation data for PCRX

Valuation Multiples - PCRX					
		Stock	Sub-Industry	Sector	S&P 500
P/S TTM	Current	4.55	2.94	2.84	3.59
	5-Year High	9.49	3.5	3.74	3.59
	5-Year Low	2.35	2.24	2.22	2.53
	5-Year Median	4.39	2.88	2.9	3.02
P/B TTM	Current	5.94	1.56	4.42	4.46
	5-Year High	13.96	13.33	5.07	4.56
	5-Year Low	3.34	1.02	2.94	2.83
	5-Year Median	5.88	2.45	4.3	3.71

As of 07/29/2020

Industry Analysis Zacks Industry Rank: Top 40% (102 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Alkermes plc (ALKS)	Neutral	3
Heron Therapeutics, Inc. (HRTX)	Neutral	3
Eli Lilly and Company (LLY)	Neutral	3
MerckCo., Inc. (MRK)	Neutral	3
MyoKardia, Inc. (MYOK)	Neutral	2
Novartis AG (NVS)	Neutral	3
Pfizer Inc. (PFE)	Neutral	3
Teva Pharmaceutical Industries Ltd. (TEVA)	Neutral	3

Industry Comparison Industry: Medical - Drugs				Industry Peers		
	PCRX	X Industry	S&P 500	ALKS	LLY	NVS
Zacks Recommendation (Long Term)	Outperform	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	1	-	-	3	3	3
VGM Score	C	-	-	D	C	B
Market Cap	2.22 B	141.61 M	22.69 B	3.00 B	154.71 B	193.19 B
# of Analysts	8	3	14	8	6	5
Dividend Yield	0.00%	0.00%	1.8%	0.00%	1.83%	2.38%
Value Score	D	-	-	D	B	A
Cash/Price	0.14	0.24	0.07	0.16	0.01	0.03
EV/EBITDA	47.01	-2.65	13.11	-26.97	25.68	13.64
PEG Ratio	1.20	1.18	3.05	NA	1.52	1.82
Price/Book (P/B)	5.94	3.34	3.15	2.82	48.39	3.59
Price/Cash Flow (P/CF)	30.53	12.94	12.28	32.52	22.84	10.69
P/E (F1)	27.64	16.70	22.27	NA	23.73	14.88
Price/Sales (P/S)	5.10	6.45	2.46	2.58	6.70	4.01
Earnings Yield	3.68%	-14.75%	4.25%	-0.21%	4.22%	6.72%
Debt/Equity	0.94	0.01	0.75	0.26	4.37	0.48
Cash Flow (\$/share)	1.73	-0.51	6.94	0.58	7.08	7.90
Growth Score	B	-	-	D	C	B
Hist. EPS Growth (3-5 yrs)	59.97%	6.78%	10.85%	NA	16.98%	2.64%
Proj. EPS Growth (F1/F0)	16.32%	14.01%	-7.70%	-105.28%	12.83%	8.28%
Curr. Cash Flow Growth	83.37%	2.87%	5.31%	-4.72%	-7.51%	4.27%
Hist. Cash Flow Growth (3-5 yrs)	69.95%	6.05%	8.55%	-0.32%	9.27%	7.11%
Current Ratio	5.37	3.70	1.31	2.69	1.11	0.81
Debt/Capital	48.36%	5.91%	44.23%	20.48%	81.39%	32.25%
Net Margin	-0.02%	-126.65%	10.45%	-10.87%	23.97%	14.96%
Return on Equity	13.89%	-62.98%	14.99%	4.46%	194.18%	24.14%
Sales/Assets	0.54	0.31	0.53	0.65	0.59	0.40
Proj. Sales Growth (F1/F0)	-0.48%	0.00%	-1.97%	-13.92%	6.79%	5.03%
Momentum Score	D	-	-	A	C	D
Daily Price Chg	1.44%	0.00%	1.52%	-6.29%	-0.55%	0.48%
1 Week Price Chg	-5.68%	-1.33%	0.37%	1.70%	-3.87%	-4.48%
4 Week Price Chg	-0.79%	0.00%	5.44%	-4.30%	-0.95%	-3.92%
12 Week Price Chg	26.31%	8.32%	15.38%	32.24%	3.24%	-1.10%
52 Week Price Chg	20.12%	-5.69%	-1.61%	-18.35%	48.46%	-7.83%
20 Day Average Volume	741,252	272,612	1,846,377	1,568,630	2,396,370	1,433,784
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	12.95%	0.00%	0.27%	9.04%	0.00%	0.50%
(F1) EPS Est 12 week change	20.60%	0.00%	-0.85%	9.04%	0.10%	0.67%
(Q1) EPS Est Mthly Chg	5.34%	0.00%	0.13%	0.00%	-0.56%	-2.84%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	D
Growth Score	B
Momentum Score	D
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.